Optum and Mayo Clinic have partnered to launch Optum Labs, an open facility designed to enable collaborative research and innovation focused on better patient care.
“Mayo Clinic’s extensive clinical insights with Optum’s healthcare claims information will help doctors better understand all aspects of the patient care experience and refine approaches to care that consistently help patients achieve the best outcomes,” Optum’s Jeffrey Smith, director, strategic outreach, Corporate Communications, told Formulary.
The partnership was started by bringing together Optum’s information assets, technologies, knowledge tools, and scientists in a state-of-the-art facility designed in Cambridge, Mass. “Optum Labs provides an environment where the healthcare industry can come together to combine information and ideas that benefit patients today while also driving long-term improvements in the delivery and quality of care,” Smith said.
“We believe this is the largest effort of its type-combining clinical and claims information-in the country. We must be creative about building relationships with other organizations to improve healthcare for Americans so we will be asking others to join our effort,” Smith added. “By working together and sharing information with partners on a national scale, we will develop a detailed, analysis-based image of the healthcare landscape that we believe will offer new insights into solving our national healthcare problems.”
The success of Optum Labs depends on a range of partners, according to Smith, who said that the facility is actively engaged in discussions with other provider organizations, pharmaceutical companies, academic institutions, commercial and government payers, and other health-system stakeholders.
“With Optum Labs, partners will now be able to better understand the full scope of the patient’s healthcare experience,” Smith said.
Examples of the work of Optum Labs scientists include measuring the best treatments for the serious blood cancer, chronic myelogenous leukemia (CML); developing applications that measure the relative cost effectiveness of medical devices; analyzing how to improve the diagnosis of hepatitis C; and increasing the understanding of health disparities among the elderly.
“By combining clinical and claims data, we have a much broader view into each scenario,” Smith said.
Optum Labs is a dedicated research unit, and it is not designed to be a profit-driven undertaking. Optum is funding the launch of Optum Labs.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.